MetaCap

Aspen Neuroscience (ASPE) vs Contineum Therapeutics (CTNM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aspen Neuroscience is the larger company by market cap ($361.2 million vs $340.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASPE-16.59%CTNM-7.56%
+16%-3%-23%
Oct 30, 20261 yearNov 20, 2026
ASPE-16.59%CTNM-7.56%
+6%-6%-18%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASPE versus CTNM key metrics
MetricASPECTNM
Share price$12.42$8.68
Market cap$361.16M$340.83M
1-day change+0.24%-3.98%
YTD return—-24.06%
1-year return—-20.69%
EPS (TTM)$-4.89$-1.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-59.98M
52-week high$14.90$17.79
52-week low$11.20$6.73
Distance from 52-week high-16.64%-51.19%
Analyst consensus—buy
Avg. price target upside—+146.89%
Average volume352.42K776.03K
Shares outstanding29.08M35.35M
Employees12051
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aspen Neuroscience

ASPE stock →

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Contineum Therapeutics

CTNM stock →

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

ASPE vs CTNM FAQ

Which is bigger, Aspen Neuroscience or Contineum Therapeutics?

Aspen Neuroscience (ASPE) is larger, with a market capitalization of $361.16M compared with $340.83M for Contineum Therapeutics (CTNM).

Are Aspen Neuroscience and Contineum Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons